GREY WOLF THERAPEUTICS - Key Persons
Job Titles:
- Chartered Member of the CIPD
- Head of People
With over 25 years working as an HR specialist, Andrea has successfully delivered projects around organisation design, TUPE, large scale redundancies, performance design, culture and employee engagement, leadership and employee development.
Previously, Andrea worked for Berendsen UK Ltd as HR Director for the Hospitality Business Line where she was responsible for the HR function for 3000 employees across UK, Ireland, Denmark and Sweden.
Andrea is a Chartered Member of the CIPD, a Mental Health First Aider and a registered practitioner in DISC and Hogan psychometric testing
Andy is the IT Manager at M:M Bio. He has over 20 years of experience in the IT sector.
In his role, he is responsible for maintaining security and developing the IT systems of the M2M ecosystem supporting the IT operations of the wider group.
Previously, Andy has led the IT service for various organisations including a multinational engineering company, a residential special needs school and a national trade association.
Job Titles:
- Chief Business Officer
- Chief Operating Officer
Andy is the COO / CBO at Grey Wolf Therapeutics, and brings a strong track record of building teams that deliver results. He has built businesses across multiple geographies and portfolios from start-up biotech to big pharma commercialisation, with notable leadership as the former CEO and President of Otsuka Pharmaceutical Company Europe. Andy is passionate about creating a culture that helps people achieve their full potential, and is a values-driven, pragmatic business leader who believes in innovative science to find new solutions for people living with the worlds most challenging illnesses.
Anil is passionate about translating novel science into transformative medicines. He currently serves as Chief Scientific Officer at OncoResponse, a company discovering cancer immunotherapies by interrogating the human immune system. He is also on the board of Surefire Medical.
Anil is the former Vice President of Early Oncology Development at AbbVie and Head of AbbVie's Redwood City site. During his tenure at AbbVie, he oversaw the global regulatory approvals of Empliciti in multiple myeloma and Zinbryta in multiple sclerosis. As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases.
Anil has held senior roles in the US, Japanese and German biopharma / biotechnology industry for over 30 years leading to the approval of Prosorba in rheumatoid arthritis and talaporfin sodium in non-small cell lung cancer.
Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.
Job Titles:
- Member of the BOARD
- Board Member - General Partner at Canaan ( West Coast )
- Member of the Kauffman Fellows Program
Brent joined Canaan in 1999 as a member of the Kauffman Fellows Program and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent's current investments and board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, device maker for chronic back pain Relievant MedSystems, life sciences tool company Unchained Labs, and pain management developer Semnur. His previous companies include Dexcom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), AtheroMed (acquired by VOLC); Durata Therapeutics (DRTX), Data Sciences International (acquired by HBIO); Elevation Pharmaceuticals (acquired by DNPUF); and Spinifex (acquired by NVS). Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit. Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.
Carolina is originally from São Paulo, Brazil, and moved to the UK in 2014. She can speak English, Portuguese, and Spanish.
Carolina graduated from Oxford Brookes University with a BSc (Hons) in Biomedical Science and is a Biotech Associate, Operations at M:M Bio. Carolina supports the M:M ecosystem by delivering professional and efficient operational and administrative support, with a focus on corporate governance and document management. Prior to joining M:M Bio Carolina worked in the Medical Communications Industry as a Project Coordinator.
Job Titles:
- Project Manager
- Project Manager at M
Clare, a Project Manager at M:MBio, combines her passion for an agile mindset with a diverse background. With expertise in delivering healthcare solutions in developing nations and R&D projects in the petrochemical and biotech space. She thrives in navigating complex projects and inspiring teams to achieve their best."
Job Titles:
- Member of the BOARD
- Board Member - Industry Expert Director
A medical doctor with a PhD in immunology, Dr Thierry Hercend has acquired more than 30 years of experience in the academic sector and the pharmaceutical industry in various therapeutic fields, including oncology and inflammatory diseases. Since 2006, Thierry has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Thierry was Vice President in charge of the therapeutic oncology sector for Aventis. From 1998 to 2002, Thierry was Vice President (Europe) for research at Vertex Pharmaceuticals. He entered the pharmaceutical industry in 1990 at Roussel-Uclaf as Director of Therapeutic Immunology and then Scientific Director of the Health Division. Before joining the industrial sector, Thierry was responsible for the Immuno-Hematology laboratory at Gustave Roussy Villejuif Institute, France ; director of the INSERM U333 unit dedicated to the immunology of tumors ; and professor of immunology at Université de Médecine-Paris XI, France. Thierry is the author of more than 120 publications in oncology, autoimmune diseases and transplantation.
Job Titles:
- ADVISOR
- Associate Professor in Cancer Immunology at the University of Southampton Cancer Research Centre
- Associate Professor of Cancer Immunology, University of Southampton
Dr. Edd James is an Associate Professor in Cancer Immunology at the University of Southampton Cancer Research Centre. Dr. James leads a group that focuses on understanding the mechanisms behind the immunodominance of antigens in tumours and investigates the role antigen processing and presentation play in generating immune responses. He has made seminal contributions to the understanding of the way in which members of the antigen presentation pathway modulate antigen processing in cancer and autoimmune disease.
Dr. James sits on the Editorial board of Journal of vaccines and immunology and on the Editorial advisory board of Immunology news. Dr. James graduated in Microbiology from the University of Bristol in 1997 and completed his PhD at Imperial college London in 2001. He was awarded a Wellcome Trust International Travelling Fellowship and held post-doctoral positions at the University of California at Berkeley and University of Southampton.
Job Titles:
- ADVISOR
- Chief Data Science Officer at Monte Rosa Therapeutics
Dr. John Castle is Chief Data Science Officer at Monte Rosa Therapeutics. Dr. Castle has deep expertise in biomarkers and therapy development using computational immunology, bioinformatics, biotechnology, and genomics. Having built translational bioinformatics and genomics units focused on immunotherapies, Dr. Castle pioneered the computational approach to the identification of immunogenic peptides for anti-tumor immunity. His bioinformatics approach has revolutionized Agenus' neoantigen vaccine platform, now in clinical testing. Prior to joining Agenus, he served as associate director at Rosetta lnpharmatics/Merck & Co. and subsequently served as the co-director at the Biomarker Development Center of Translational Oncology at the University of Mainz, Germany. Dr. Castle was the director of bioinformatics at BioNTech AG (DE). Dr. Castle studied physics at Rice University (U.S.), in Gdttingen (DE), and in Canberra (Fulbright to AUS) and received a Ph.D. in geophysics from the University of Washington in Seattle.
Dr. Michael Koslowski has over 20 years experience in R&D, specialising in discovery and development of immunotherapeutic drugs within academia and biopharmaceutical companies. Currently, Michael serves as Chief Medical Officer at GammaDelta Therapeutics, a London based biotech company developing novel cell therapies for immunotherapy of cancer. Prior, he was EVP R&D and Chief Medical Officer at Mission Therapeutics, where he was responsible for developing the company's pipeline deubiquitinating enzyme inhibitors. As VP Clinical Sciences & Early Development at Glenmark Pharmaceuticals he led all clinical activities across therapeutic areas, including Glenmark's first oncology development programme. At Boehringer Ingelheim he was Global Head of Translational Medicine Experts, responsible for building a new Translational Medicine Group from scratch. Prior to Boehringer Ingelheim, Michael was founding member and Group Leader of New Targets & Antibody Development at Ganymed Pharmaceuticals. Michael held academic positions such as Principal Scientist in Experimental and Translational Oncology at the University of Mainz and University of the Saarland. Michael has a degree in Medicine from the University of Cologne (Germany) and a habilitation degree in Molecular Medicine from the University of Mainz (Germany).
Job Titles:
- Head of Bioinformatics at M
Dr. Mitul Patel is a Head of Bioinformatics at M:M Bio where he works with their ecosystem companies to provide Bioinformatics services. His focus areas are : Bioinformatics infrastructure, pipeline development, big data analysis and software development.
Prior to M:M Bio, Mitul was the Head of Bioinformatics at BerGenBio where he worked on several clinical trials leading translational analysis to provide new insights into pharmacodynamic and predictive biomarkers, and managing the Bioinformatics team.
He has also held senior positions at Engitix and Immunocore where he was involved in several big data projects, utilizing and analyzing Omics data from next-generation sequencing projects and databases. He developed many computational pipelines and software applications to analyse RNAseq, TCR, whole exome and Single-cell data in immuno-oncology/fibrosis, including the application of machine learning/AI. Mitul received his Bachelor's in Bioinformatics in India before emigrating to the UK to obtain an MSc in Bioinformatics from the University of Wolverhampton and Ph.D. in advanced Bioinformatics from the University of Greenwich. With Bioinformatics roots, Mitul has worked in genomics for nearly 10 years and presented his research at several national and international meetings and has published several peer-reviewed papers.
Job Titles:
- ADVISOR
- Independent Consultant
- Chemistry and Drug Discovery Consultant
Dr. Paul Leeson is a medicinal chemistry and drug discovery consultant with >35 years' experience in major pharmaceutical companies: Smith Kline and French, Merck Sharp and Dohme, Wyeth (USA), AstraZeneca, and GlaxoSmithKline. Since 2014 he has advised pharmaceutical companies, start-ups, and academia. At AstraZeneca (1997-2011) Paul was head of medicinal chemistry at the Charnwood site, and as leader of the Global Chemistry Forum he was responsible for the company's chemistry strategy. Paul's drug discovery contributions have been in the cardiovascular, neuroscience, respiratory and inflammation therapy areas. He has a special interest in compound quality, for which he received the Nauta Award from the European Federation of Medicinal Chemistry in 2014. Paul has a PhD from the University of Cambridge and holds an honorary professorship at the University of Nottingham.
Job Titles:
- ADVISOR
- Independent Consultant
Eliot has more than 25 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Immunocore from 2015. Prior to that he was Chief Executive Officer of biotechnology companies Creabilis Therapeutics (now Sienna Biopharmaceuticals) and Solace Pharmaceuticals Inc. Other previous roles include Head of Development and Operations for the EU and Asia at Pfizer. Eliot is Non-Executive Chairman of Avacta PLC and of MedCity, which promotes the Life Sciences in the "Golden Triangle", and founding Chairman of Advanced Oxford, which aims to grow the innovation economy in the Oxford region. He is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool, a Board member of OSCHR (Office for Strategic Coordination of Health Research) and the National Genomics Board. He holds a PhD from University of Liverpool and an MBA from Henley Management College.
Job Titles:
- Member of the BOARD
- Senior Investment Manager
- Board Member - Investment Manager at BPC
- Fund Her North As a Founding Member
Emma is a Senior Investment Manager in the British Patient Capital Direct Investments team, where she focuses on opportunities in the life sciences.
Emma joined the BPC team in September 2021 at the launch of Future Fund: Breakthrough and has led investments into companies spanning novel therapeutic modalities and technologies driving efficiencies in the life sciences sector. Previously, Emma spent three years investing in a broad array of life sciences companies for the Greater Manchester and Cheshire Life Sciences Fund managed by Catapult Ventures.
Emma also joined Fund Her North as a founding member with the goal of increasing access to finance for female entrepreneurs in the North of England and has a background in Neuroscience.
Georgia is a Biomedical Sciences B.Sc. (Hons) graduate from Durham University and is Operations Project Support for M:M Bio. Before joining M:M Bio Georgia worked in Australia supporting the operations and running of a Girls Boarding House.
Georgia supports Grey Wolf Therapeutics via the M:M Bio Ecosystem with a wide range of daily operational tasks and long-term projects.
Henry graduated from Cardiff University with a BSc (Hons) in Biomedical Science in 2021. Intrigued by Biomedical research, he completed his MRes at Cardiff University gaining a distinction, with his Masters' thesis studying the inhibition of ligand-gated cation channels and subsequent release of inflammatory mediators in osteoarthritis. Henry works as a Biotech Associate primarily supporting M:M and Grey Wolf Therapeutics in both the operational and R&D projects.
Job Titles:
- Senior Data Scientist at M
Ionut is a Senior Data Scientist at M:M Bio. In his role, Ionut is supporting exploratory analysis and data mining using computational learning techniques within the Scientific Community.
Before joining M:M Bio, Ionut worked for Achilles Therapeutics in London, supporting data analysis and software development within two major clinical trials. During the onset of the COVID-19 pandemic, Ionut worked at Charles River in Cambridge, where he proudly committed his time for improving the UK testing capacity through data-driven decisions.
Ionut holds an MSc in Bioinformatics from the University of Birmingham, followed by an internship at Cambridge Cancer Genomics where he applied machine learning concepts for gathering insights into cancer growth mechanisms. Prior to this, Ionut studied Biochemistry at the University of Southampton where he focused on using data mining for assessing signalling pathways interactions in colorectal cancer.
Job Titles:
- Project Manager
- Project Manager at Grey Wolf Therapeutics Ltd
Jessica is currently Project Manager at Grey Wolf Therapeutics Ltd and has extensive experience working across a range of functional areas within a "semi-virtual" biotech company. She has been involved in world-class drug development projects, from preclinical discovery stage right through to IND-enabling and Phase 1/2 clinical stage. She has over 10 years of experience working in the biotech industry and has provided operational expertise to set up small biotech companies at the point of seed investment and Series A financing. She manages key supplier relationships to keep R&D studies and programs progressing in line with scientific aims, corporate goals and financial budgets.
The highlight of her career has been as Executive Assistant/ Project Coordinator (US & AUS) for Spinifex Pharmaceuticals. Jessica played a role in the success of Spinifex's acquisition by Novartis in July 2015. This buyout was centered around Spinifex's lead clinical candidate, EM401,
Joana is an Honours in Financial Accounting (B.Com) graduate from the North West University in South Africa. She completed her 3 years articles at an Audit and Accounting practice followed by a further year as a supervisor in the Accounting & Advisory department with exposure to different sectors including Aviation and the Medical field.
Joana also has over 10 years experience in the service and retail industry.
In her role at Grey Wolf Therapeutics Limited , Joana supports the implementation & maintenance of financial processes & systems to achieve accuracy of information for reporting & decision-making.
Job Titles:
- ADVISOR
- Principal Research Fellow, Vice President and Head of Biological Sciences at Vertex Pharmaceuticals
- VP, Vertex Pharmaceuticals
John Pollard is a Principal Research Fellow, Vice President and Head of Biological Sciences at Vertex Pharmaceuticals. John holds a degree in Chemistry with PhD and Post- Doctoral studies in a variety of Bio-Organic and Biochemical fields. During his near 20-year tenure at Vertex, John has held many senior positions including Department Head, with responsibility for over 50 scientists covering multiple disciplines such as structural biology, biochemistry, cell and animal pharmacology. John has also served as global research lead for the oncology portfolio and has extensive experience leading numerous oncology research and development projects from target validation through lead optimization to Ph2 proof-of-concept. In this role, John has worked across diverse cancer biologies including cell cycle, DNA damage repair, metabolism, survival and immunooncology. John has led numerous collaborations with academia and the pharmaceutical industry, has presented at many international meetings and has published over 30 academic papers.
Job Titles:
- ADVISOR
- Independent Consultant
Julian Golec PhD FRSC retired as Senior Vice President of R&D and site head for Vertex Pharmaceuticals (Europe) Ltd (VPEL) during summer 2016. He trained as a chemist at the University of Hull and has 30 years experience in drug discovery. Prior to Vertex, Julian worked for Hoechst Marion Roussel (later Aventis) and then Xenova, a Slough based biotech. He left HMR in 1996 as project leader of a joint project with Vertex that led to the first interleukin-1 converting enzyme inhibitor (pralnacasan) for arthritis. He then became Director of Research at Xenova where he moved Traiquidar, a multidrug resistance inhibitor for oncology, into the clinic and helped secure a multi million pound collaboration with Eli Lilly on PAI-1 inhibitors for cardiovascular diseases.
Involvement with Vertex started as a collaborator in 1993, then as senior manager at the company in 1998. He served on the VPEL Board of Directors between 2001 and 2013. As a contributor to the management of Vertex's global research strategy, he provided strong advocacy for the company's continued investment in UK research and development. Vertex Pharmaceuticals Inc pioneered the use of structural biology in the small molecule drug discovery process. Major successes included the discovery of treatments for HIV (agenerase), hepatitis C (telepravir), and cystic fibrosis (ivacaftor and lumacaftor). Julian remained intimately involved with the early drug discovery process through the Abingdon research group. Their recent successes included the first Aurora/ Abl inhibitor and the first ATR inhibitor to enter clinical trials.
In Summary, Julian Golec has gained breadth of experience from having been involved, scientifically and managerially, in a company's progress, from its beginnings to its current multibillion-dollar status.
Kate is a 1 st Class (Hons) Biomedical Sciences (B.Sc.) graduate from Lancaster University. During her time at university, Kate was fortunate to gain paid internships at small and large pharmaceutical manufacturing sites, as well as a cancer research studentship. This gave her an introduction to life as a scientist, alongside her studies.
Prior to joining Grey Wolf, Kate worked as a scientific editor at a content marketing agency for two years. She supported the delivery of global marketing campaigns with high value scientific manufacturers and provided key insights into their target audiences.
In her role at Grey Wolf Therapeutics, Kate supports both the R&D and operations teams with daily tasks and long-term projects.
Job Titles:
- Chief Executive Officer - M
- Co - Founder of Both Pathios Therapeutics
Kirsty brings over 25 years of experience in tech and biotech commercialization to the team. Kirsty is a Co-Founder of both Pathios Therapeutics, an early stage biotechnology company and, Molecule 2 Medicine, which is a UK based consulting firm assisting global clients with the discovery, development and commercialisation of new human therapeutics, including new company formation and associated activities. From 2004-2010, she was Director and CEO of various technology ventures focused in the speech recognition and AI space. She holds a BA from University of Queensland, completed her honours year at Monash University, Australia and her MBA at the University of Melbourne.
Kris is Head of Biology at Grey Wolf Therapeutics where he leads the implementation of the preclinical and translational biology strategy for the different drug discovery programmes. He brings over 20 years of cell signalling expertise acquired at the interface of innovation between academia, the biotech and pharmaceutical sectors. His research in cell signalling pathways has been specifically applied to drug discovery in the fields of oncology and immunology.
During a distinguished career in academia, Kris was first to characterize several potent and selective chemical probes of kinases that are now widely used in the field. He also identified a new drug target which led academic drug discovery units as well as biotech companies to establish programmes, with one now undergoing PhII clinical trials. More recently, Kris crafted his art as Principal Scientist at Sygnature Discovery and Director of Kinase Biology at Exscientia where he led projects delivering 3 clinical candidates, all of which are currently being evaluated in clinical trials.
Kris holds a PhD in Medical Sciences from the Radboud University Nijmegen in the Netherlands and completed post-doctoral studies at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee in Scotland.
Lisa is the Director of Finance at Grey Wolf Therapeutics. Having completed a BA (Hons) in Accountancy & Management Control, Lisa qualified as a Chartered Accountant ICAEW with Mazars in 2000. Since qualifying, Lisa has held various finance and operational roles within both the private and public sector with a focus on working with SMEs and she brings this experience with her to her role here at Grey Wolf.
Job Titles:
- IT Support Technician for M
- IT Systems Engineer
Lorena is IT Support Technician for M:M Bio where she supports the development and maintenance of the IT Systems across the Ecosystem.
Originally from Brazil, she has a BSc in Physiotherapy from the University of Brasilia, a Postgraduate Diploma in Oncology Care from the Federal University of Sao Paulo and 5 years experience in Healthcare. Lorena has recently completed the AWS re/Start programme and has an AWS Cloud Practitioner Certificate.
Job Titles:
- Member of the BOARD
- Partner
- Board Member - Partner at Pfizer Ventures
Marie-Claire is a Partner on the Pfizer Ventures Team and an Executive Director in Emerging Science & Innovation at Pfizer. In her current role she is responsible for investing in early-stage biotech companies and supporting them in advancing emerging science to deliver new medicines to patients. She is on the Board of Directors for DEM Biopharma and Grey Wolf Therapeutics.
Marie-Claire holds a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She conducted postdoctoral work at Yale University and has spent 25 years at Pfizer holding various leadership positions supporting small molecule discovery. As part of her former responsibilities, Marie-Claire founded and led the Primary Pharmacology Group for 13 years during which time they were responsible for the identification of nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), and ten additional therapeutics that are currently in clinical trials. She has additional experience leading compound management, high throughput ADME, data support and management, genetically modified models, preclinical bioimaging and biobanking.
Marie-Claire was recognized as a PhRMA ‘We Work For Health' Champion in 2018 and was a 2019 finalist for the CT Women of Innovation Award. She is active on multiple community non-profit boards and is the Executive Sponsor for the Pfizer Women's Resource Group in CT.
Job Titles:
- Director of Medicinal Chemistry
Martin is a medicinal chemist with more than 25 years' experience in the pharmaceutical industrial ranging from start-up to medium-sized companies, as the founding scientist, group Director and more recently in an independent consultancy capacity. Martin has an established track record of successful team leadership and innovation with >50 scientific publications and >30 patent applications, many of which are granted and the basis of drug candidates that have entered the clinic.
As Senior Director of Exploratory Projects at Shire Pharmaceuticals, he established an internal Medicinal Chemistry Team to provide creative and patentable new product ideas for Shire Speciality Pharma, based around a fully outsourced model. This was followed by Leadership and Executive Board level representation for Medicinal Chemistry at Sygnature Discovery, a leading UK provider of discovery services to the pharmaceutical industry.
Martin holds a PhD in medicinal chemistry from the University of Birmingham and completed postdoctoral research studies at the Medical Research Council LMB in Cambridge.
Michael is a Project Support at Grey Wolf Therapeutics. In his role, Michael supports management of intellectual property and external communications alongside R&D projects.
Michael obtained his MRes at Xi'an Jiaotong-Liverpool University in Suzhou, China. His Masters' thesis, investigating the role of GITR signalling in macrophages, was carried out at Soochow University, Suzhou. Prior to this, Michael studied Pharmacology with Industrial Experience at The University of Manchester, during which he completed a placement year in the Cancer Immunotherapy and Immune Modulation department at Boehringer Ingelheim in Vienna, Austria. He has also had summer work experience at multiple other labs including The Sackler Institute of Pulmonary Pharmacology at King College London.
Job Titles:
- Head of Clinical Operations
Natalie is Head of Clinical Operations at Grey Wolf Therapeutics, where she provides program oversight for the timely, quality preparation and execution of the international clinical development program.
With over 20 years of management experience in both small biotechs and large pharmaceutical companies, she is an accomplished clinical leader within her field. She has a proven success record in operationalising Phase 1-3 clinical research studies with a focus in oncology, as well as the successful submission of CTAs, INDs, BLAs.
She has global experience running trials in many regions including EU, UK, Australia and US and brings a passion for innovative and patient focused research. Natalie has a B.Sc. (Hons) from Leeds University, UK.
Job Titles:
- ADVISOR
- Head of Immunopeptidomics, University of Oxford
Dr. Nicola Ternette studied Physics and Biochemistry at the Universities of Rheinische Friedrich-Wilhelms-Universität Bonn, Ernst-Moritz-Arndt-Universität Greifswald, and Ruhr-Universität Bochum, Germany from 1997-2003.
She was awarded her PhD in 2007 from the Ruhr-Universität Bochum, Germany, on her work on the development of DNA vaccines for prevention of respiratory syncytial virus (RSV) infection. Her thesis identified the mechanisms for previously observed ineffectiveness of DNA vaccination utilising expression of RNA virus antigens (1) and suggested an alternative functional approach for the development of DNA vaccines for use in RSV vaccination strategies (2).
After her PhD, Dr. Ternette was keen to pursue a post-doctoral research project abroad, and she joined the team of Professor Benedikt Kessler's group at the University of Oxford in 2008 with fellowships from the German Academic Exchange Service (DAAD) and the German Research Foundation (DFG). During her postdoctoral time, she concentrated on applying nanoflow ultra-performance liquid chromatography tandem mass spectrometry (nUPLC-MS) to understand modulation of cellular pathways in viral infection (3) and cancer (4-7).
Dr. Ternette then specialised in the sequencing of MHC-associated peptidomes using nUPLC-MS for its application as antigen discovery strategy for the development of T cell vaccines in viral infection (8). In 2014, she was awarded the Nuffield Department of Medicine Leadership Fellowship. Her group has now expanded their expertise to deep sequencing of immunopeptidomes in multiple pathogen infection models, analysis of the antigenic landscape of solid tumours, and haematological cancers and characterisation of antigens involved in autoimmune diseases (9-11).
Job Titles:
- Chief Executive Officer
- Co - Founder
- Founder
- Member of the BOARD
Peter is founder and Chief Executive Officer of Grey Wolf, setting up the company in 2017 with Tom McCarthy, Executive Chairman, and also co-founder of Pathios Therapeutics and ThirtyFiveBio. Peter is an accomplished drug discovery executive with over 19 years of experience in biomedical research leading drug discovery projects across disease areas.
Prior to Grey Wolf he was at Vertex Pharmaceuticals, where he led drug discovery projects and had responsibility for leading a number of target identification teams, and before Vertex he was a research fellow at the Medical Research Council investigating the pathophysiology and underlying mechanisms of neurodegeneration and publishing multiple first and co-author publications. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.
Job Titles:
- Business Intelligence Manager for M
Phill is the Business Intelligence Manager for M:M Bio where he provides commercial insight for the group. In his role, he is responsible for strategy, market & financial analytics, and competitive intelligence for Grey Wolf Therapeutics. He has a strong passion for solving real world problems using science and technology - aligning him well with Grey Wolf's goals.
Phill has a background in consumer business and tech, working in large multinational companies in a variety of commercial sales and project management roles, as well and more recently in the Canadian tech startup ecosystem as a software developer and product manager. He has always been passionate about supporting science commercially, and worked as a founder for a company supporting scientists to gain access to emerging alternative funding sources in North America.
Originally from New Zealand, Phill has just moved to Oxford UK from Vancouver where he has been living since 2017. He is a recent MBE (Bioscience Enterprise) graduate from the University of Cambridge in 2021, with prior undergraduate studies at the Otago University in Chemistry and Business.
Job Titles:
- Member of the BOARD
- Board Member - Investment Professional at Earlybird VC
Rabab Nasrallah, PhD is a Healthcare Investment Professional at Earlybird Venture Capital, investing in early-stage companies across digital health, medical devices, diagnostics, R&D platform technologies, and biopharma. Currently, Rabab is a board member of Grey Wolf Therapeutics and a board observer of ImCheck Therapeutics, Atlantic Therapeutics, Argá Medtech, and Priothera.
Before joining Earlybird, Rabab was the program manager at INCUBATE, a startup accelerator at the University of Sydney, Australia. With an extensive research background, Rabab has held roles in leading global research organizations in Australia and the UK, including The George Institute for Global Health, Lowy Cancer Research Centre, Cancer Research UK, and Cambridge University.
Rabab has received her PhD in regenerative medicine from UNSW Sydney and Cancer Research UK Manchester Institute. She has also completed a postdoctoral fellowship at the Babraham Institute in Cambridge, focusing on therapeutics in the immuno-oncology and auto-immune disease space.
Working as a System Developer in M:M Bio for Developing and supporting AWS/LINUX environments across the ecosystem. Originally from India, Rahul has a Bachelors degree in Computer science from University of Kerala, India.
Rahul has experience of 8 years in well known IT firms like Wipro LTD, Oracle India PVT LTD and Marlabs Innovations PVT LTD, handling multiple clients from Telecom and Healthcare companies.
Job Titles:
- Member of the BOARD
- Board Member - Partner at Andera Partners ( BioDiscovery )
Job Titles:
- Member of the BOARD
- Board Member - Senior Associate at Oxford Science Enterprises
Sally joined Oxford Science Enterprises in February 2021, bringing over 8 years of oncology-focused research experience from world-leading academic institutions.
She works on uncovering new opportunities across the Life Sciences and supports the creation of new biotech businesses as well as the management of the existing portfolio.
Sally was previously an Anderson Cancer Center Post-Doctoral Fellow at the Rockefeller University in New York where her research focused on genetic instability at the very earliest stages of cancer development. Prior to this, she completed a PhD at the Francis Crick Institute in London where she uncovered an important role for polypoid cells in driving cancer evolution.
Academic research that Sally has contributed to has been published in leading journals including Nature Genetics, Nature Communications and Cancer Discovery.
Sally has also studied corporate finance at NYU, and consulted for The Solution Lab.
Job Titles:
- Company Secretary
- Company Secretary for M
Sam Harris is the Company Secretary for M:M Bio. She graduated from Aston University in 1999 with a BSc with Honours degree in International Business and Modern Languages (French), which included a year at one of France's top Business Schools - EDHEC.
Since leaving University she has spent the last 20 years of her career providing EA & operational support to C Suite Executives and their Leadership teams, ensuring the smooth running of their businesses incorporating all aspects of people, places and processes. Sam has worked in several industries including Consumer Packaging, Mobile software, Information Technology, and prior to joining M:M Bio, 7 years within the advertising technology sector.
With more than 30 years of experience, Sam has a proven track record of providing EA support to C-Suite executives across multiple industries within both private and public sectors.
In her role as Executive Assistant, she identifies and reacts to operational needs and alleviates pressure points. Working with internal and external stakeholders she manages a diverse range of resources to quickly assess and prioritise situations, planning and implementing actions efficiently.
Job Titles:
- ADVISOR
- Chief Executive Officer of Pathios Therapeutics
Stuart is Chief Executive Officer of Pathios Therapeutics and brings over 20 years experience in scientific leadership and drug discovery expertise. Stuart has worked across several therapeutic areas inlcuding CNS disorders, immunology and oncology and has deep expertise in guiding early stage drug discovery programs from inception toward clinical development. Stuart has gained wide-ranging experience from positions in both academic and industrial settings. Previous positions include Research Fellow and Senior Lecturer at Cardiff University, Principal Research Scientist at Eli Lilly and most recently, Senior Director at Vertex Pharmaceuticals. He holds a a PhD in Neuroscience from Cardiff University, a BSc in Pure and Applied Mathematics and an MSc in Electronic Engineering.
Tom Lillie is CMO at Grey Wolf Therapeutics, a company focused on using ERAP inhibition to overcome resistance in immuno-oncology. Dr Lillie completed his undergraduate training at Brasenose College, University of Oxford, where he was awarded a first-class degree in pharmacology, cell biology and immunology, before earning his doctorate in cell biology from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honours distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.
Tom has led global, regional and affiliate medical teams, encompassing both early and late-stage clinical development and medical affairs functions. He has extensive experience in clinical research in phase 1 - phase 4, and in supporting regulatory, safety and reimbursement interactions. During his clinical and industry career he has specialised in oncology & haematology, but has also worked in cardiovascular, metabolic, vaccine, anti-infective and neurologic disease areas.
Job Titles:
- Co - Founder
- Executive Chairman
- Member of the BOARD